Cargando…
Mucopolysaccharidosis Type II: A Kenyan Case Series
Hunter syndrome, or mucopolysaccharidosis type 2 (MPS2), is a lysosomal storage disorder associated with the involvement of multiple organs such as the central nervous system, hepatomegaly, musculoskeletal, respiratory, cardiac, and hearing. This is due to the accumulation of glycosaminoglycans in b...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716217/ https://www.ncbi.nlm.nih.gov/pubmed/34976050 http://dx.doi.org/10.1155/2021/2328402 |
_version_ | 1784624275951452160 |
---|---|
author | Mungai, L. N. Wainaina Njeru, C. M. Nyamai, L. A. Maina, M. |
author_facet | Mungai, L. N. Wainaina Njeru, C. M. Nyamai, L. A. Maina, M. |
author_sort | Mungai, L. N. Wainaina |
collection | PubMed |
description | Hunter syndrome, or mucopolysaccharidosis type 2 (MPS2), is a lysosomal storage disorder associated with the involvement of multiple organs such as the central nervous system, hepatomegaly, musculoskeletal, respiratory, cardiac, and hearing. This is due to the accumulation of glycosaminoglycans in body tissues leading to organ failure. Since the laboratories in Kenya do not screen for metabolic diseases, there is the likelihood of assumption that these patients do not exist. These first cases were referred from the eastern part of Kenya where the majority of inhabitants are from the same ethnic community. It was noted that there was increased mortality among boys below the age of 20 years, and hence, the families sought for help in the national referral and teaching hospital. The case series is meant to show that these cases exist and the majority of the patients may be dying before the diagnosis is made. There are no data on MPS2 from Kenya, and the prevalence and incidence are unknown. In this retrospective study, we present a case series of 6 Kenyan boys with MPS2 from a national referral hospital. They were part of 17 patients who had had their blood analyzed for metabolic diseases. All of them were symptomatic with varying degrees of central nervous system involvement. They had undetectable levels of iduronate-2-sulfatase (I2S) enzyme, and three genetic mutations were detected in the IDS gene. |
format | Online Article Text |
id | pubmed-8716217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-87162172021-12-30 Mucopolysaccharidosis Type II: A Kenyan Case Series Mungai, L. N. Wainaina Njeru, C. M. Nyamai, L. A. Maina, M. Int J Endocrinol Research Article Hunter syndrome, or mucopolysaccharidosis type 2 (MPS2), is a lysosomal storage disorder associated with the involvement of multiple organs such as the central nervous system, hepatomegaly, musculoskeletal, respiratory, cardiac, and hearing. This is due to the accumulation of glycosaminoglycans in body tissues leading to organ failure. Since the laboratories in Kenya do not screen for metabolic diseases, there is the likelihood of assumption that these patients do not exist. These first cases were referred from the eastern part of Kenya where the majority of inhabitants are from the same ethnic community. It was noted that there was increased mortality among boys below the age of 20 years, and hence, the families sought for help in the national referral and teaching hospital. The case series is meant to show that these cases exist and the majority of the patients may be dying before the diagnosis is made. There are no data on MPS2 from Kenya, and the prevalence and incidence are unknown. In this retrospective study, we present a case series of 6 Kenyan boys with MPS2 from a national referral hospital. They were part of 17 patients who had had their blood analyzed for metabolic diseases. All of them were symptomatic with varying degrees of central nervous system involvement. They had undetectable levels of iduronate-2-sulfatase (I2S) enzyme, and three genetic mutations were detected in the IDS gene. Hindawi 2021-12-22 /pmc/articles/PMC8716217/ /pubmed/34976050 http://dx.doi.org/10.1155/2021/2328402 Text en Copyright © 2021 L. N. Wainaina Mungai et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Mungai, L. N. Wainaina Njeru, C. M. Nyamai, L. A. Maina, M. Mucopolysaccharidosis Type II: A Kenyan Case Series |
title | Mucopolysaccharidosis Type II: A Kenyan Case Series |
title_full | Mucopolysaccharidosis Type II: A Kenyan Case Series |
title_fullStr | Mucopolysaccharidosis Type II: A Kenyan Case Series |
title_full_unstemmed | Mucopolysaccharidosis Type II: A Kenyan Case Series |
title_short | Mucopolysaccharidosis Type II: A Kenyan Case Series |
title_sort | mucopolysaccharidosis type ii: a kenyan case series |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716217/ https://www.ncbi.nlm.nih.gov/pubmed/34976050 http://dx.doi.org/10.1155/2021/2328402 |
work_keys_str_mv | AT mungailnwainaina mucopolysaccharidosistypeiiakenyancaseseries AT njerucm mucopolysaccharidosistypeiiakenyancaseseries AT nyamaila mucopolysaccharidosistypeiiakenyancaseseries AT mainam mucopolysaccharidosistypeiiakenyancaseseries |